Key Summary Points {#FPar1}
==================

***Why carry out this study?***Long-term treatment adherence is important to ensure good clinical management of type 2 diabetes; however, up to 50% of people with this disease discontinue treatment by 1 year.Little is known about why people discontinue treatment for type 2 diabetes and the experiences that lead to discontinuation.This study aimed to better understand the reasons for treatment discontinuation among people with type 2 diabetes in the USA and UK, including the treatments people discontinue, their reasons for discontinuing treatment and any factors which might have prevented treatment discontinuation.***What was learned from the study?***The main reasons for treatment discontinuation overall were side effects---mostly gastrointestinal and weight gain---followed by treatment efficacy issues, while the main factors that would have prevented discontinuation were more efficacious treatments with fewer side effects and an improved care pathway.Our results emphasise the need for more focused medical education and improved communication to help improve therapeutic adherence, and highlight the importance of understanding patient preferences when prescribing existing medications and developing new therapies.

Introduction {#Sec1}
============

Diabetes affects approximately 463 million people worldwide, of whom 90% have type 2 diabetes mellitus (T2DM) \[[@CR1]\]. In the USA in 2018, 26.8 million adults were living with diagnosed diabetes and a further 7.3 million were estimated to have undiagnosed diabetes \[[@CR2]\]. In the UK in 2019, there were 3.9 million people living with diagnosed diabetes \[[@CR3]\]. As T2DM is a chronic disease, long-term treatment adherence is important to ensure good clinical management \[[@CR4]\]. Up to 50% of people with T2DM discontinue treatment by 1 year \[[@CR5]\].

Lack of adherence and persistence with treatment in T2DM acts as a barrier to achieving glycaemic control \[[@CR6]\], increases the risk of microvascular and macrovascular complications \[[@CR7]\], and increases healthcare costs \[[@CR5], [@CR8]\]. Patient-related factors that contribute to poor adherence are perceived treatment efficacy, fear of hypoglycaemia, the complexity and burden of treatment regimens and inconvenience associated with treatment, cost, and lack of diabetes knowledge \[[@CR5]\]. However, little is known about why people discontinue treatment for T2DM and the experiences that lead to discontinuation \[[@CR4]\]. An understanding of treatment and care preferences is important when currently available diabetes treatments are being prescribed or when new therapies are being developed.

This study aimed to better understand why treatment discontinuation occurs among people with T2DM in the USA and UK by conducting an online study on Carenity, a global patient community.

Methods {#Sec2}
=======

Study Design and Participants {#Sec3}
-----------------------------

An online questionnaire was presented to people with T2DM in the USA and UK on PatientLive^®^, a platform of Carenity, a global online patient community. The questionnaire was designed by Sanofi and validated by Carenity. People registered on the Carenity T2DM community in the USA and UK were invited to participate in the survey via email.

Participants were included if they were an adult (at least 18 years of age) with T2DM and had stopped a T2DM treatment within the past 6 months. As the survey was an ad hoc (not systematic) opinion survey and no personal data were processed, ethics committee approval was not required in either the USA or the UK. For the USA, only research involving human subjects should be submitted for approval, which is not applicable for the present study. Confirmation that ethics committee approval was not required in the UK was obtained via the UK Health Research Authority website (<https://www.hra-decisiontools.org.uk/ethics/>). Participant consent was obtained online at the time of registration to Carenity, prior to survey completion.

Outcomes {#Sec4}
--------

Participants were asked to name the T2DM treatment that they had discontinued in the last 6 months. They were then asked one closed-ended and three open-ended questions to determine the reasons why they originally initiated the now-discontinued treatment, the reasons for them discontinuing the treatment, how discontinuation could have been prevented, and what additional information would have improved the experience with the discontinued treatment.

Data Analysis {#Sec5}
-------------

A sample size of 100 participants by geographic area was initially targeted. Data were collected for 98 respondents in the USA and 90 respondents in the UK. Thematic qualitative analysis was performed on respondents' answers to the open-ended questions. Cross-analysis between type of treatments and other respondents' answers was also performed. Excel^®^ 2013 was used for all data processing and analyses.

Results {#Sec6}
=======

Participant Disposition {#Sec7}
-----------------------

Of the 188 respondents to the survey, 161 responded that they had stopped a T2DM treatment in the past 6 months and were eligible to complete the whole survey. Of these 161 respondents, 89 were from the USA and 72 from the UK.

Treatments Discontinued {#Sec8}
-----------------------

The majority of respondents had discontinued one treatment in the past 6 months, except six respondents who reported discontinuing two treatments. The most commonly discontinued treatments spontaneously mentioned by participants were oral antidiabetic drugs (OADs; 93/161 \[58%\]), and among those who discontinued OADs, metformin was the most common OAD discontinued (55/93 \[59%\]), followed by sitagliptin (12/93 \[13%\]) and glipizide (7/93 \[8%\]). Sodium--glucose linked transporter 2 inhibitors (SGLT2is) were discontinued in 5/161 (3%) participants. Injectable antidiabetic therapies were also commonly discontinued (53/161 \[33%\]), with insulin (40/161 \[25%\]) being the most commonly discontinued followed by glucagon-like peptide-1 receptor agonists (GLP-1 RAs; 13/161 \[8%\]). In total, 12 (7%) respondents who stopped taking a treatment in the past 6 months did not name the treatment, while one respondent reported discontinuing a glucose-monitoring system and one did not provide detail beyond that it was inhibitors.

OADs and insulin were the main T2DM treatments discontinued regardless of country of residence.

Data on length of time the respondent spent on treatment prior to discontinuation was spontaneously reported by 34 (21%) respondents; 17 (50%) of these respondents reported discontinuing treatment within the first year and 68% (23/34) reported having taken the treatment for less than 2 years.

Reasons for Initiating Treatment {#Sec9}
--------------------------------

The main reasons given for treatment initiation are shown in Fig. [1](#Fig1){ref-type="fig"}. The most common reason reported by participants for treatment initiation was because their general practitioner or diabetologist (69/161 \[43%\]) prescribed the treatment, irrespective of country and treatment initiated. The second most common reason was uncontrolled HbA1c, affecting 32% (52/161) of all respondents, 37% (33/89) of US respondents and 26% (19/72) of UK respondents.Fig. 1Reasons for treatment initiation among respondents with type 2 diabetes in the USA and UK. GP general practitioner, HbA1c glycated haemoglobin

Reasons for Discontinuing Treatment {#Sec10}
-----------------------------------

The main reasons given for treatment discontinuation are shown in Fig. [2](#Fig2){ref-type="fig"}. Overall, for all respondents and most of the treatments, side effects were the most common reason reported for treatment discontinuation (57/161 \[35%\]), primarily gastrointestinal disorders (10/57 \[18%\]), weight gain (10/57 \[18%\]), and hypoglycaemia (9/57 \[16%\]).Fig. 2Reasons for treatment discontinuation among respondents with type 2 diabetes in the USA and UK

Drug efficacy issues (42/161 \[26%\]; mainly no perceived positive effect 15/42 \[36%\]) and decision of the medical team (38/161 \[24%\]) were also common reasons reported for discontinuation. Of those who discontinued as a result of a decision of the medical team, 20/38 (53%) reported stopping their medication while 18/38 (47%) reported changing their medication (3/38 \[8%\] to injectable medication, 2/38 \[5%\] to oral medication, 1/38 \[3%\] to a different type of insulin, and 12/38 \[32%\] to an unspecified medication). Importantly, 19% (31/161) of respondents stated that they discontinued treatment because their disease was under control.

The reasons given for treatment discontinuation differed by type of treatment. Side effects were reported as the most common reason for discontinuation of OADs (35/93 \[38%\]), followed by decision of the medical team (24/93 \[26%\]) and drug efficacy issues (22/93 \[24%\]). Side effects were also the most common reason for discontinuation of insulin (11/40 \[28%\]), followed by drug efficacy issues and decision of the medical team (each reported by 10/40 \[25%\] respondents). Side effects, drug efficacy issues, and decision of the medical team were reported equally as the reason for discontinuing SGLT2is (each reported by 2/5 \[40%\] respondents), and drug efficacy issues were the most commonly reported reason for discontinuation of GLP-1 RAs (5/13 \[38%\]), followed by side effects (4/13 \[31%\]). The reason for treatment discontinuation did not tend to depend on the country of residence, except for economic issues, which were reported by 14/89 (16%) US respondents but only 3/72 (4%) UK respondents.

Factors to Prevent Treatment Discontinuation {#Sec11}
--------------------------------------------

The key factors that would have prevented discontinuation are shown in Fig. [3](#Fig3){ref-type="fig"}. An improved care pathway (45/161 \[28%\]), such as more support and information from the healthcare professional (HCP; 12/45 \[27%\]) and better drug dosage (8/45 \[18%\]), was the main factor reported that would have prevented discontinuation. Many respondents also reported more efficacious treatments with fewer side effects (41/161 \[25%\]), and economic solutions (16/161 \[10%\]) as factors that would have prevented discontinuation. However, 48/161 (30%) respondents mentioned that nothing could have prevented them from stopping their treatment.Fig. 3Factors that would have prevented treatment discontinuation among respondents with type 2 diabetes in the USA and UK

When assessed by treatment group, respondents stated most often that nothing could have prevented them from discontinuing OADs (29/93 \[31%\]), other injectable antidiabetics (7/13 \[54%\]) and SGLT2is (2/5 \[40%\]). However, for insulin, the most common factor that would have prevented discontinuation was more support during the care pathway (17/40 \[43%\]). Exempting economic solutions, which was a more notable reason in the USA (12/89 \[13%\]) than the UK (4/72 \[6%\]), improvements that would have prevented treatment discontinuation did not differ by country.

The information that respondents reported would have been useful to improve their understanding of and their experience with their discontinued treatments is shown in Fig. [4](#Fig4){ref-type="fig"}. Medical information (56/161 \[35%\]), help with disease management (24/161 \[15%\]), increased and informative patient--physician interaction (12/161 \[7%\]), and information linked to the care pathway (9/161 \[6%\]) were the most needed forms of information. These responses did not differ by country of residence or treatment discontinued. Some respondents (64/161 \[40%\]) said that there was no additional information that would have been useful to improve their understanding and experience of the discontinued treatment.Fig. 4Information needed to improve the treatment experience among respondents with type 2 diabetes in the USA and UK

Discussion {#Sec12}
==========

Good glycaemic control is essential for individuals with diabetes to avoid the risk of developing microvascular and macrovascular complications \[[@CR9]\]. However, evidence indicates that many people with T2DM discontinue treatment within 1 year of initiation \[[@CR5]\]. The results of this questionnaire-based study confirm these findings among people with T2DM in the USA and UK. OADs were the most commonly reported treatment discontinued, which is in line with prescription data that shows metformin to be the most commonly prescribed first-line antidiabetic treatment and sulfonylureas the most commonly prescribed second-line antidiabetic treatment \[[@CR10]\].

Reasons for T2DM treatment discontinuation identified in the literature include perceived treatment efficacy, fear of hypoglycaemia, the complexity and burden of treatment regimens and inconvenience associated with treatment, cost, and lack of diabetes knowledge \[[@CR5]\]. Other studies assessing individual preference in the treatment of T2DM typically did not fully explore the real reasons for discontinuation but focused on preferences overall through discrete-choice experiments (DCE) \[[@CR11]--[@CR15]\]. Indeed, DCE offer multiple hypothetical medication profiles for people to choose between that can differ by treatment aspects (including number of pills, oral vs injectable therapy, costs, etc.), treatment satisfaction or barriers to intensification \[[@CR11]--[@CR15]\]. The current study allowed participants to share their own response for reasons they perceived to be important specifically for improving adherence and persistence with their therapy on the basis of their experience.

Results from the present study confirm the results from previous literature \[[@CR5]\]. Side effects, primarily gastrointestinal disorders, weight gain, and hypoglycaemia, were the main reasons overall for treatment discontinuation among the respondents of this study (35%), indicating a need for well-tolerated treatments. About one-quarter of respondents participating in this study also reported drug efficacy issues as a cause of stopping treatment, of which no perceived positive effect was the most common reason in these respondents. However, it is important to consider that for some therapies, such as insulin, the perceived lack of efficacy may be a consequence of suboptimal titration due to patient and physician concerns such as weight gain, fear of hypoglycaemia, multiple daily injections, complexity of therapy or therapeutic burden \[[@CR16], [@CR17]\]. Indeed, results of an online survey in the USA, France and Germany showed that 32--42% of individuals with diabetes receiving basal insulin therapy were unaware of the need to titrate their insulin and 74% of physicians reported fear of hypoglycaemia as a barrier to optimal titration \[[@CR16]\]. It is important to note that another one-fifth of respondents reported that they had discontinued treatment as their disease was now under control. For various chronic conditions, a correlation has been observed between treatment adherence and perceived need (including whether an individual regarded a medication necessary, helpful, wanted, or right for them, whether they understood the drug or illness, or their condition sufficiently improved), corroborating this finding \[[@CR18]\].

Cost was highlighted as a reason for discontinuation by 16% of US respondents, compared with only 4% of UK respondents, which could be attributed to the direct out-of-pocket costs for individuals in the USA \[[@CR19]\] compared with costs being covered by the National Health Service in the UK \[[@CR20]\]. In people with T2DM who discontinue or do not properly adhere to their therapy, there is an increased risk of microvascular and macrovascular complications \[[@CR7]\], which can in turn increase healthcare costs further \[[@CR5], [@CR6]\]. Therefore, affordable therapies have the potential to reduce current and future costs of living with diabetes.

In this study, the most frequently reported reason for initiating the discontinued therapy was at the guidance of the treating physician. Coupled with an improvement in the care pathway (including more information from the doctor) being reported as a key factor for preventing discontinuation in both countries, this emphasises the need for focused education and improved communication between the physician and the patient to enhance treatment understanding and experience. Current guidelines in the USA and UK stress the importance of structured and individualised education \[[@CR21], [@CR22]\] and European Association for the Study of Diabetes/American Diabetes Association guidelines state the importance of shared decision-making \[[@CR8], [@CR23]\]. However, our results indicate that, despite these guidelines, individuals still perceived a need for improved care pathways and may benefit from additional information and support. Without proper communication on the rationale behind initiating therapies and shared decision-making, individuals with diabetes may not fully understand the implications of discontinuing their therapy or may be receiving therapies that they consider to be unsuitable for them, potentially making discontinuation of the treatment more likely.

While 40% of respondents reported that no information would have prevented them from discontinuing treatment, it is important to note that a third of respondents reported that medical information would have improved their experience and 15% said they would have liked support, stressing the importance of adequate and appropriate patient engagement. Given the number of respondents who reported initiating therapy because it was prescribed by their doctor (43%) and not due to underlying causes, it is possible that respondents had too little information to understand why the new therapy was initiated and what should be evaluated to stop discontinuation. As such, they reported that no information would have prevented them from discontinuing treatment. Discontinuation for these participants might also have been due to burden of disease or complexity of currently available diabetes therapies. An improvement in treatment, including fewer side effects and increased efficacy, would have helped prevent treatment discontinuation in a quarter of respondents, highlighting that individualised treatment that fits the needs of each person is important among those with T2DM.

Participants in this study were recruited from a patient social platform, which has several benefits. Firstly, patients in social networks are generally more willing to share their experiences and feel free to express themselves anonymously and confidentially without their HCP's involvement, which has been shown to limit social desirability bias \[[@CR24]\]. Secondly, such networks provide an opportunity to collect patient-reported outcomes that complement and add value to clinical data while empowering people and putting them at the centre of their own care. The use of patient platforms, however, limits the researcher's ability to include individuals who do not have access to the online tool and thus may lead to a potential recruitment bias \[[@CR24]\]. This study captured patient-reported outcomes with no access to the participants' medical records, so it could not be confirmed whether reasons given for discontinuation were accurate (i.e. whether respondents reached glycaemic control or if the HCP had prescribed a decrease or change to their prescription). Another limitation of this study was that data were collected from a survey with a relatively small sample size. Additionally, data analyses were descriptive and variables such as education and income were not captured.

On the basis of the results of our survey, there is an opportunity to further communicate specifically on side effects and drug efficacy issues. Patient--HCP discussions before treatment initiation may help people with T2DM to better understand their options and allow for individualisation of therapy, as recommended by the American Diabetes Association/European Association for the Study of Diabetes guidelines \[[@CR8], [@CR23]\]. This may lead to better patient experience, reported outcomes, and adherence. There is a wealth of patient education materials available to HCPs to help facilitate engagement with their patients.

Conclusion {#Sec13}
==========

Despite the availability of multiple classes of drugs, and multiple therapies within each drug class, glycaemic control rates remain suboptimal and a high proportion of people with T2DM do not continue on their prescribed therapies \[[@CR5]\]. The current study provides important insights into the attitudes of people with T2DM that impact treatment adherence. The data from this survey highlight patient perspectives on reasons for treatment discontinuation among people with T2DM in the USA and UK and provide focal points for communication for these individuals when they are initiating new therapies \[[@CR5]\]. Such communication may help more people with T2DM improve treatment adherence and persistence \[[@CR5]\], and subsequently achieve glycaemic control and prevent short- and long-term complications. Furthermore, data from such surveys emphasise the importance of considering the perspective of individuals early in the drug development process.
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